Floatz logo

CLOSTRIDIUM BUTYRICUM MIYAIRI 588

Sarcomatoid Renal Cell Carcinoma

City of Hope Medical Centerother_biologicalPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Sarcomatoid Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Sorafenib
National Cancer Institute (NCI)
Phase 2BB
Nivolumab
City of Hope Medical Center
Phase 3BB
Bms-907351
City of Hope Medical Center
Phase 3BB
Ipilimumab
City of Hope Medical Center
Phase 3BB
gw786034
Mayo Clinic
Phase 2B

View all 16 →

Same molecule, other indications

CLOSTRIDIUM BUTYRICUM MIYAIRI 588 is also rated in:

Stage IV Renal Cell Cancer AJCC v8Dormant
BB
Indicative ·
70 / 100
View asset →
Metastatic Clear Cell Renal Cell CarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
renal cell carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →